Retinal imaging detects early Parkinson
- Trial ID
- NCT07244640
- Official Title
- Clinical Study on Non-Invasive Fundus Retinal Detection Technology for Early Diagnosis of Parkinson's Disease
- Goal
- Retinal imaging detects early Parkinson
- Status
- RECRUITING
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Study Type
- OBSERVATIONAL
- Enrollment
- 200 participants
- Conditions
- Parkinson's Disease (PD)
- Interventions
- non-invasive fundus retinal detection
Plain-Language Summary
They want to find eye-based signs that could help detect Parkinson's disease earlier by comparing retinal images from people with early PD, atypical parkinsonism, essential tremor, and healthy volunteers. The approach uses non-invasive fundus retinal imaging to take detailed photos of the back of the eye, looking for changes in retinal nerve layers or blood vessel patterns that might correlate with Parkinson's, so no injections or surgery are involved. The study is enrolling people aged 40 to 80, including Parkinson's patients diagnosed within five years at Hoehn and Yahr stage 1 to 2.5, people with atypical or secondary parkinsonism within five years, people with essential tremor, and healthy controls. People with severe eye disease, major heart/liver/kidney problems, active infections or systemic inflammatory diseases, pregnancy, inability to tolerate the imaging, or significant psychiatric disorders are excluded.
Locations
- 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Frequently Asked Questions
- What is this trial testing?
- This trial is studying non-invasive fundus retinal detection. They want to find eye-based signs that could help detect Parkinson's disease earlier by comparing retinal images from people with early PD, atypical parkinsonism, essential tremor, and healthy volunteers. The approach uses non-invasive fundus retinal imaging to take detailed photos of the back of the eye, looking for changes in retinal nerve layers or blood vessel patterns that might correlate with Parkinson's, so no injections or surgery are involved. The study is enrolling people aged 40 to 80, including Parkinson's patients diagnosed within five years at Hoehn and Yahr stage 1 to 2.5, people with atypical or secondary parkinsonism within five years, people with essential tremor, and healthy controls. People with severe eye disease, major heart/liver/kidney problems, active infections or systemic inflammatory diseases, pregnancy, inability to tolerate the imaging, or significant psychiatric disorders are excluded.
- Who can participate?
- Participants must be between 40 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 3 years and 1 month.